WASHINGTON (November 23, 2013) The U.S. Food and Drug Administration has approved a new drug from Johnson & Johnson for use in treating chronic hepatitis C infections.
The drug is a protease inhibitor that blocks a protein needed by the virus to replicate.
The Johnson & Johnson drug is designed to eliminate hepatitis C, the most common form of the liver-destroying virus.
It is a daily pill taken in combination with the long-established drug cocktail used to treat the most common form of the virus.
The FDA's decision came less than a month after an FDA advisory panel voted unanimously in favor of approving the treatment.
More than 3 million people in the U.S. have hepatitis C, a blood-borne disease that causes 15,000 deaths a year.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or email@example.com.